Brief: Enlivex Announces New Preclinical Data In Murine Mesothelioma Model
12/09/2022 14:40
Sept 12 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES NEW PRECLINICAL DATA IN MURINE
MESOTHELIOMA
MODEL SHOWING A SUBSTANTIAL SURVIVAL BENEFIT WITH ALLOCETRA AS
MONOTHERAPY AND IN COMBINATION WITH CISPLATIN AT THE ESMO
CONGRESS 2022
Source text for Eikon: ID:nGNX492j4H
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment